WS #11719
AstraZeneca's Wainua drug failed to meet primary endpoint in heart disease trial, wiping out £20bn in market cap.
AstraZeneca Drug Trial Failure
AstraZeneca's Wainua drug failed to meet primary endpoint in heart disease trial, wiping out £20bn in market cap.